<table id="id_87dca7d7-d62b-4cfb-abcf-1ab118151a8e" width="430.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_48b375dc-7170-493a-a0ec-1bfe57a5b992">Table 11: Effect of Other Drugs on Voriconazole Pharmacokinetics</caption>
<col align="left" width="34.0%"></col>
<col align="center" width="33.0%"></col>
<col align="center" width="33.0%"></col>
<thead>
<tr id="id_c65732c6-1eef-432e-a46c-e5f9923f943c" stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">Drug/Drug Class<br/>(Mechanism of Interaction by the Drug)</td>
<td align="left" stylecode="Rrule" valign="top">Voriconazole Plasma Exposure<br/>(C<sub>max</sub> and AUC<sub>Ï„</sub> after<br/>200 mg Q12h)</td>
<td align="left" stylecode="Rrule" valign="top">Recommendations for Voriconazole<br/>Dosage Adjustment/Comments</td>
</tr>
</thead>
<tbody>
<tr id="id_2de98396-60f7-4756-b613-ee62ca68e310" stylecode="Toprule">
<td align="left" stylecode="Lrule Botrule" valign="top">Rifampin<footnote id="id-385d863f-ba97-4e97-b60c-270ae48f3bb8">Results based on <content stylecode="italics">in vivo</content> clinical studies generally following repeat oral dosing with 200 mg Q12h voriconazole to healthy subjects</footnote>, and Rifabutin<footnoteref idref="id-385d863f-ba97-4e97-b60c-270ae48f3bb8"></footnoteref>
<br/>(CYP450 Induction)</td>
<td align="left" stylecode="Botrule" valign="top">Significantly Reduced</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_8ecfb754-1235-41c1-981a-b6be7c77110d">
<td align="left" stylecode="Lrule" valign="top">Efavirenz<footnote id="id-efd1b403-25d5-4963-b4f6-62279c87b07b">Results based on <content stylecode="italics">in vivo</content> clinical study following repeat oral dosing with 400 mg Q12h for 1 day, then 200 mg Q12h for at least 2 days voriconazole to healthy subjects</footnote>
<br/>(CYP450 Induction) </td>
<td align="left" valign="top">Significantly Reduced</td>
<td align="left" stylecode="Rrule" valign="top">When voriconazole is coadministered with efavirenz, voriconazole maintenance dose should be increased to 400 mg Q12h and efavirenz should be decreased to 300 mg Q24h (See <content stylecode="bold">
<linkhtml href="#i4i_clinical_pharmacology_id_a7dc4ff3-a754-4ca9-a070-ff5efd1049b0">CLINICAL PHARMACOLOGY</linkhtml>
</content> and <content stylecode="bold">
<linkhtml href="#i4i_section_id_a197dd6f-9575-4548-83bc-b9d0459bbeb3">DOSAGE AND ADMINISTRATION-Dosage Adjustment</linkhtml>)</content>
</td>
</tr>
<tr id="id_fee340c9-9c78-44f7-b8b1-5272476352ff">
<td align="left" stylecode="Lrule" valign="top">High-dose Ritonavir (400mg Q12h)<footnoteref idref="id-efd1b403-25d5-4963-b4f6-62279c87b07b"></footnoteref>
<br/>(CYP450 Induction)</td>
<td align="left" valign="top">Significantly Reduced</td>
<td align="left" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_771f3e2e-483b-4888-a1a2-cabfbd3fe670">
<td align="left" stylecode="Lrule" valign="bottom">Low-dose Ritonavir (100mg Q12h)<footnoteref idref="id-efd1b403-25d5-4963-b4f6-62279c87b07b"></footnoteref>
<br/>(CYP450 Induction)</td>
<td align="left" valign="middle">Reduced</td>
<td align="left" stylecode="Rrule" valign="bottom">Coadministration of voriconazole and low-dose ritonavir (100 mg Q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</td>
</tr>
<tr id="id_a15e44bc-b6d3-4bb1-b7e4-079f1654262f">
<td align="left" stylecode="Lrule Botrule" valign="top">Carbamazepine <br/>(CYP450 Induction)</td>
<td align="left" stylecode="Botrule" valign="top">Not Studied In Vivo or In Vitro, but Likely to Result in Significant Reduction</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_e757af52-f67a-42cf-a774-61289a0f2cbe">
<td align="left" stylecode="Lrule Botrule" valign="top">Long Acting Barbiturates <br/>(CYP450 Induction)</td>
<td align="left" stylecode="Botrule" valign="top">Not Studied In Vivo or In Vitro, but Likely to Result in Significant Reduction</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_fde53c7c-2c4d-4452-8d03-b75dd791874b">
<td align="left" stylecode="Lrule Botrule" valign="top">Phenytoin<footnoteref idref="id-385d863f-ba97-4e97-b60c-270ae48f3bb8"></footnoteref>
<br/>(CYP450 Induction)</td>
<td align="left" stylecode="Botrule" valign="top">Significantly Reduced</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV every 12 hrs or from 200 mg to 400 mg orally every 12 hrs (100 mg to 200 mg orally every 12 hrs in patients weighing less than 40 kg)</td>
</tr>
<tr id="id_54d6a0e7-56db-4c8d-a9e5-77457fcad834">
<td align="left" stylecode="Lrule Botrule" valign="top">St. John's Wort<br/>(CYP450 inducer; P-gp inducer)</td>
<td align="left" stylecode="Botrule" valign="top">Significantly Reduced</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr id="id_7746d6ed-8cd3-4e9c-b26e-4639caf1dbfb">
<td align="left" stylecode="Lrule" valign="top">Oral Contraceptives<footnoteref idref="id-385d863f-ba97-4e97-b60c-270ae48f3bb8"></footnoteref> containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)</td>
<td align="left" valign="top">Increased</td>
<td align="left" stylecode="Rrule" valign="top">Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives</td>
</tr>
<tr id="id_113c6223-7e66-483f-81f8-569d600621a8">
<td align="left" stylecode="Lrule Botrule" valign="top">Other HIV Protease Inhibitors <br/>(CYP3A4 Inhibition)</td>
<td align="left" stylecode="Botrule" valign="top">In Vivo Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure<br/>
<br/>In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir<br/>
<br/>Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV protease inhibitors</td>
</tr>
<tr id="id_6e5ba550-d66c-4161-a004-4003d16eca43">
<td align="left" stylecode="Lrule" valign="top">Other NNRTIs<footnote id="id-b5a6e936-6c64-4b98-9c2e-ef1567094f21">Non-Nucleoside Reverse Transcriptase Inhibitors</footnote>
<br/>(CYP3A4 Inhibition or CYP450 Induction) </td>
<td align="left" valign="top">In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</td>
<td align="left" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to voriconazole</td>
</tr>
<tr id="id_0ca51cce-10ad-4574-b658-763f0f600824" stylecode="Botrule">
<td align="left" stylecode="Lrule" valign="top"></td>
<td align="left" valign="top">
<br/>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure) </td>
<td align="left" stylecode="Rrule" valign="top">
<br/>Careful assessment of voriconazole effectiveness</td>
</tr>
</tbody>
</table>